Amneal Pharmaceuticals Inc (NASDAQ:AMRX) has a beta value of 1.32 and has seen 3.21 million shares traded in the last trading session. The company, currently valued at $1.95B, closed the last trade at $6.34 per share which meant it gained $0.43 on the day or 7.28% during that session. The AMRX stock price is 0.63% off its 52-week high price of $6.30 and 80.44% above the 52-week low of $1.24. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.23 million shares traded. The 3-month trading volume is 1.44 million shares.
Amneal Pharmaceuticals Inc (NASDAQ:AMRX) trade information
Sporting 7.28% in the green in last session, the stock has traded in the green over the last five days, when the AMRX stock price touched $6.34 or saw a rise of 1.86%. Year-to-date, Amneal Pharmaceuticals Inc shares have moved 4.45%, while the 5-day performance has seen it change 19.40%. Over the past 30 days, the shares of Amneal Pharmaceuticals Inc (NASDAQ:AMRX) have changed 7.46%. Short interest in the company has seen 1.83 million shares shorted with days to cover at 1.33.
Amneal Pharmaceuticals Inc (AMRX) estimates and forecasts
Figures show that Amneal Pharmaceuticals Inc shares have underperformed across the wider relevant industry. The company’s shares have gained 44.75% over the past 6 months, with this year growth rate of -17.19%, compared to 11.90% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2024 fiscal year revenue. Growth estimates for the current quarter are -25.00% and -31.60% for the next quarter. Revenue growth from the last financial year stood is estimated to be 9.00%.
3 analysts offering their estimates for the company have set an average revenue estimate of $620.36 million for the current quarter. 3 have an estimated revenue figure of $653.16 million for the next quarter concluding in Jun 2024. Year-ago sales stood $557.54 million and $599.05 million respectively for this quarter and the next, and analysts expect sales will grow by 11.30% for the current quarter and 9.00% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -23.74% over the past 5 years. Earnings growth for 2024 is a modest -8.31% while over the next 5 years, the company’s earnings are expected to decrease by -1.50%.
AMRX Dividends
Amneal Pharmaceuticals Inc is expected to release its next earnings report between February 29 and March 04 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Amneal Pharmaceuticals Inc (NASDAQ:AMRX)’s Major holders
Insiders own 53.15% of the company shares, while shares held by institutions stand at 36.13% with a share float percentage of 77.11%. Investors are also buoyed by the number of investors in a company, with Amneal Pharmaceuticals Inc having a total of 203 institutions that hold shares in the company. The top two institutional holders are Fosun International Ltd with over 21.52 million shares worth more than $66.72 million. As of Jun 29, 2023, Fosun International Ltd held 13.96% of shares outstanding.
The other major institutional holder is Vanguard Group Inc, with the holding of over 13.14 million shares as of Jun 29, 2023. The firm’s total holdings are worth over $40.72 million and represent 8.52% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Small-Cap Index Fund. As of Jun 29, 2023, the former fund manager holds about 2.59% shares in the company for having 3.99 million shares of worth $12.37 million while later fund manager owns 3.56 million shares of worth $11.05 million as of Jun 29, 2023, which makes it owner of about 2.31% of company’s outstanding stock.
